EASDAQ: Fighting for a Lost Cause?

 
• By Melanie Senior
  
Generate a summary of this article
Listen to this article
Beta

Five years after its formation, Easdaq still hasn't given up the fight to become the pan-European market for growth stocks--but it hasn't won the war either. Despite its aim of providing growth companies with European-wide exposure, using a single regulatory environment and trading system--the Brussels-based exchange has so far failed to become the Nasdaq of Europe.

Five years after its formation, Easdaq still hasn't given up the fight to become the pan-European market for growth stocks—but it hasn't won the war, either. Despite its laudable aim—to provide growth companies with European-wide exposure, using a single regulatory environment and trading system—the Brussels-based exchange has so far failed to become the Nasdaq of Europe.

Trading volumes remain low. There are just 60 listed companies, and biotechs—with the exception of a handful including Antisoma PLC...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.